Abstract
Although current therapies for pretransplant desensitization and treatment of antibody-mediated rejection (AMR) have had some success, they do not specifically deplete plasma cells that produce antihuman leukocyte antigen (HLA) antibodies. Bortezomib, a proteasome inhibitor approved for the treatment of multiple myeloma (a plasma cell neoplasm), induces plasma cell apoptosis. In this paper we review the current body of literature regarding the use of this biological agent in the field of transplantation. Although limited experience with bortezomib may seem to show promise in the realm of transplant recipients desensitization and treatment of AMR, there is also experience that may suggest otherwise. Bortezomib's role in desensitization protocols and treatment of AMR will be defined better as more clinical data and trials become available.
Authors
6
- Rajeev Raghavan (first)
- Abdallah Jeroudi (additional)
- Katafan Achkar (additional)
- A. Osama Gaber (additional)
- Samir J. Patel (additional)
- Abdul Abdellatif (additional)
References
29
Referenced
19
10.1056/NEJM199912023412303
10.1097/TP.0b013e3181d21e7f
10.1111/j.1600-6143.2009.03001.x
{'key': '5', 'first-page': 'S1', 'volume': '9', 'year': '2009', 'journal-title': 'American Journal of Transplantation'}
/ American Journal of Transplantation (2009)10.1097/00007890-199402270-00014
/ Transplantation (1994)10.1097/00007890-200009270-00006
/ Transplantation (2000)10.1097/MOT.0b013e3283342712
10.1034/j.1600-6143.2003.00135.x
10.1111/j.1600-6143.2009.02591.x
10.1034/j.1600-6143.2003.00121.x
10.1097/01.tp.0000231922.11453.ec
10.1111/j.1600-6143.2006.01632.x
10.1097/TP.0b013e318190af83
10.1097/TP.0b013e3181a4b91b
10.1111/j.1600-6143.2008.02461.x
{'journal-title': 'Clinical transplants', 'first-page': '229', 'year': '2008', 'key': '17'}
/ Clinical transplants (2008)10.1097/TP.0b013e3181d9e1c0
10.1097/TP.0b013e3181c6ff8d
10.1111/j.1600-6143.2009.02968.x
10.1056/NEJMoa0801479
{'issue': '17', 'key': '22', 'first-page': '6316', 'volume': '9', 'year': '2003', 'journal-title': 'Clinical Cancer Research'}
/ Clinical Cancer Research (2003)10.1038/nrneph.2009.233
10.1038/nm1763
{'key': '26'}
10.1016/j.clinthera.2009.11.012
10.1038/leu.2009.83
/ Leukemia (2009)10.1056/NEJMoa030288
{'key': '30', 'first-page': '171', 'volume': '10', 'year': '2010', 'journal-title': 'American Journal of Transplantation'}
/ American Journal of Transplantation (2010){'journal-title': 'Clinical transplants', 'first-page': '339', 'year': '2009', 'key': '32'}
/ Clinical transplants (2009)
Dates
Type | When |
---|---|
Created | 14 years, 11 months ago (Sept. 27, 2010, 10:38 a.m.) |
Deposited | 8 years, 2 months ago (June 19, 2017, 6:31 a.m.) |
Indexed | 6 months, 1 week ago (Feb. 21, 2025, 11:18 a.m.) |
Issued | 15 years, 8 months ago (Jan. 1, 2010) |
Published | 15 years, 8 months ago (Jan. 1, 2010) |
Published Print | 15 years, 8 months ago (Jan. 1, 2010) |
@article{Raghavan_2010, title={Bortezomib in Kidney Transplantation}, volume={2010}, ISSN={2090-0015}, url={http://dx.doi.org/10.1155/2010/698594}, DOI={10.1155/2010/698594}, journal={Journal of Transplantation}, publisher={Wiley}, author={Raghavan, Rajeev and Jeroudi, Abdallah and Achkar, Katafan and Gaber, A. Osama and Patel, Samir J. and Abdellatif, Abdul}, year={2010}, pages={1–6} }